Simcere Pharmaceutical Group (SEHK:2096) - Aandelenkoers, Nieuws & Analyse

2096 Overzicht aandelen

2096 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 79.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 74.95% per jaar groeien

Risicoanalyse

Geen risico's gedetecteerd voor 2096 uit onze risicocontroles.

Simcere Pharmaceutical Group Limited Concurrenten

Grand Pharmaceutical Group

SEHK:512

HK$16.3b

United Laboratories International Holdings

SEHK:3933

HK$20.2b

China Medical System Holdings

SEHK:867

HK$19.9b

SSY Group

SEHK:2005

HK$11.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Simcere Pharmaceutical Group
Historische aandelenkoersen
Huidige aandelenkoers	HK$7.21
52 Week Hoogtepunt	HK$7.87
52 Week Laag	HK$4.94
Bèta	0.47
11 maand verandering	11.09%
3 maanden verandering	34.26%
1 Jaar Verandering	5.72%
33 jaar verandering	-8.85%
5 jaar verandering	n/a
Verandering sinds IPO	-34.34%

Recent nieuws en updates

Recent updates

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Jul 29

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

May 01

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Dec 29

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Jun 03

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Apr 06

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Jan 10

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Aug 16

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Jun 27

Rendement voor aandeelhouders

	2096	HK Pharmaceuticals	HK Markt
7D	6.0%	-1.6%	-0.3%
1Y	5.7%	5.9%	18.4%

Rendement versus industrie: 2096 kwam overeen met de Hong Kong Pharmaceuticals industrie, die het afgelopen jaar een rendement opleverde van 5.7 %.

Rendement versus markt: 2096 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 19.7 % opleverde.

Prijsvolatiliteit

Is 2096's price volatile compared to industry and market?
2096 volatility
2096 Average Weekly Movement	6.2%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Stabiele aandelenkoers: 2096 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van 2096 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	6,412	Jinsheng Ren	www.simcere.com

Simcere Pharmaceutical Group Limited houdt zich bezig met onderzoek, ontwikkeling, productie en verkoop van farmaceutische producten voor distributeurs en apotheekketens en andere farmaceutische fabrikanten in China. Het bedrijf richt zich op verschillende therapeutische gebieden, waaronder oncologie, centraal zenuwstelsel, auto-immuun, anti-infectie, cardiovasculair en andere. De belangrijkste producten zijn Sanbexin, een geconcentreerde oplossing van edaravone en dexborneol voor injectie; Endostar, een injectie van recombinant humaan endostatine; ENWEIDA, een injectie van envafolimab; COSELA, een trilaciclibhydrochloride voor injectie; Iremod, een iguratimod-tablet; en XIANNUOXIN, een simnotrelvir tablet/ritonavir tablet.

Simcere Pharmaceutical Group Limited Samenvatting

Hoe verhouden de winst en inkomsten van Simcere Pharmaceutical Group zich tot de beurswaarde?
2096 fundamentele statistieken
Marktkapitalisatie	HK$18.01b
Inkomsten(TTM)	-HK$1.20b
Inkomsten(TTM)	HK$6.90b

2.6x

P/S-verhouding

-15.0x

Koers/Winstverhouding

Is 2096 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2096 resultatenrekening (TTM)
Inkomsten	CN¥6.34b
Kosten van inkomsten	CN¥1.45b
Brutowinst	CN¥4.88b
Overige uitgaven	CN¥5.99b
Inkomsten	-CN¥1.10b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.44
Brutomarge	77.05%
Nettowinstmarge	-17.39%
Schuld/Eigen Vermogen Verhouding	14.5%

Hoe presteerde 2096 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.4%

Huidig dividendrendement

-37%

Uitbetalingsratio

2096 Overzicht aandelen

Beloningen

Risicoanalyse

Simcere Pharmaceutical Group Limited Concurrenten

SEHK:512

HK$16.3b

SEHK:3933

HK$20.2b

SEHK:867

HK$19.9b

SEHK:2005

HK$11.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

Now 22% overvalued

Recent updates

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

Now 22% overvalued

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug

Co-Founder recently sold HK$1.2m worth of stock

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.

Upcoming dividend of CN¥0.16 per share

Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China

Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 14%

Dividend of CN¥0.16 announced

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Consensus EPS estimates fall by 37%

Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Consensus EPS estimates fall by 35%

Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration

Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

Co-Founder recently bought HK$1.2m worth of stock

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Consensus revenue estimates fall by 22%

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Co-Founder recently sold HK$710k worth of stock

New minor risk - Insider selling

Co-Founder recently sold HK$2.3m worth of stock

Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023

Co-Founder recently bought HK$1.5m worth of stock

Upcoming dividend of CN¥0.16 per share at 2.3% yield

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Co-Founder recently sold HK$3.1m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Consensus revenue estimates fall by 13%

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Now 23% undervalued

Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director